about
The therapeutic journey of pyridazinone.The therapeutic voyage of pyrazole and its analogs: A review.Piperazine scaffold: A remarkable tool in generation of diverse pharmacological agents.Therapeutic evolution of benzimidazole derivatives in the last quinquennial period.Synthesis of pyrazole acrylic acid based oxadiazole and amide derivatives as antimalarial and anticancer agents.Molecular interactions of bisphenols and analogs with glucocorticoid biosynthetic pathway enzymes: an in silico approach.Molecular interactions of dioxins and DLCs with the xenosensors (PXR and CAR): An in silico risk assessment approach.Inhibition of Src homology 2 domain containing protein tyrosine phosphatase as the possible mechanism of metformin-assisted amelioration of obesity induced insulin resistance in high fat diet fed C57BL/6J mice.Molecular docking reveals the potential of phthalate esters to inhibit the enzymes of the glucocorticoid biosynthesis pathway.Molecular interactions of dioxins and DLCs with the ketosteroid receptors: an in silico risk assessment approach.Synthesis of Hybrids of Dihydropyrimidine and Pyridazinone as potential Anti-Breast Cancer Agents.In silico molecular interaction of bisphenol analogues with human nuclear receptors reveals their stronger affinity vs. classical bisphenol AA Review Exploring Therapeutic Worth of 1,3,4-Oxadiazole Tailored CompoundsGreen recipes to quinoline: A reviewRevealing quinquennial anticancer journey of morpholine: A SAR based reviewTargeting malaria and leishmaniasis: Synthesis and pharmacological evaluation of novel pyrazole-1,3,4-oxadiazole hybrids. Part IIDibenzepinones, dibenzoxepines and benzosuberones based p38α MAP kinase inhibitors: Their pharmacophore modelling, 3D-QSAR and docking studiesUnveiling novel diphenyl-1H-pyrazole based acrylates tethered to 1,2,3-triazole as promising apoptosis inducing cytotoxic and anti-inflammatory agents
P50
Q38559509-82D16021-750E-4541-9E99-9B940B8D1AF2Q38559961-C79C0C34-9FA6-4235-9C7C-638EBECF4711Q38574542-CA42DEC0-4CF7-4BEE-80A7-1225616F6F29Q39036446-0E4BD892-7826-428C-A5F8-F49C07241FACQ48022666-D9FC76EB-87BA-4C6B-A6F2-0987AFA622F1Q48113687-CB9EAA57-F8C5-4C86-89FC-AD54F306EE19Q48238365-E9A4E6CF-7E31-45CB-9ECC-CD6845E18365Q51066930-639B9C49-E421-4939-8EE9-86622AF75E14Q51635413-350040FE-8075-46A2-BD8F-B877879B323CQ52677469-3BD777C1-3496-40CC-8A34-1D1925D6E6D0Q52871273-1E243797-A832-4989-902E-8CD709048637Q56986432-20B84D85-803D-4C3B-9A7C-43C5654D151FQ57464537-351E9E1E-EE79-405E-9516-F7BBE089D131Q90800498-118A0711-09E1-4807-9ACD-7AF059628408Q91680145-988DE915-9390-45BF-B027-0FF82F0E10F6Q92407501-0F92D434-8853-435D-8050-0D5903C4C2BFQ92586859-E5678D83-45F5-4915-96EE-B554DDD49A52Q92892057-39C5D0A8-2B72-4FD5-847E-B66731D03DC2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mohemmed Faraz Khan
@ast
Mohemmed Faraz Khan
@en
Mohemmed Faraz Khan
@es
Mohemmed Faraz Khan
@nl
type
label
Mohemmed Faraz Khan
@ast
Mohemmed Faraz Khan
@en
Mohemmed Faraz Khan
@es
Mohemmed Faraz Khan
@nl
prefLabel
Mohemmed Faraz Khan
@ast
Mohemmed Faraz Khan
@en
Mohemmed Faraz Khan
@es
Mohemmed Faraz Khan
@nl
P106
P1153
56802965900
P31
P496
0000-0003-3846-1577